Table 1.
Clinicopathological characteristics of the metastatic breast cancer
| Characteristics | Screening stage n=26 (%) | Validation stage n=67 (%) |
|---|---|---|
| Age (years) median (range) | 55 (35-72) | 53 (30-80) |
| ECOG | ||
| 0, 1 | 25 (96.2) | 63 (94.0) |
| 2 | 1 (3.8) | 4 (6.0) |
| Histology | ||
| IDC | 25 (96.2) | 58 (86.5) |
| ILC | 1 (3.8) | 3 (4.5) |
| Others | 0 | 6 (9.0) |
| Histologic grading | ||
| Grade 1 | 7 (35) | 24 (35.8) |
| Grade 2 | 8 (40) | 31 (46.3) |
| Grade 3 | 5 (25) | 12 (17.9) |
| AJCC stage | ||
| Stage I | 1 (3.8) | 4 (6.0) |
| Stage II | 12 (46.2) | 30 (44.8) |
| Stage III | 8 (30.8) | 24 (35.8) |
| Stage IV | 3 (11.5) | 5 (7.5) |
| Unknown | 2 (7.7) | 4 (6.0) |
| Internalorgan metastasis (liver, lung, brain) | 14 (53.8) | 32 (47.8) |
| More than 2 sites of metastasis | 12 (46.2) | 28 (41.8) |
| Clinical response | ||
| PR | 10 (38.5) | 33 (49.3) |
| PD | 16 (61.5) | 34 (50.7) |
| PFS (months) | 3.2 (2.9-3.6) | 5.1 (2.0-8.2) |
| OS (months) | 21.0 (14.1-28.0) | 18.1 (10.3-25.8) |
Note: ECOG: Eastern Cooperative Oncology Group; IDC: Invasive ductal carcinoma; ILC: Invasive lobular carcinoma; PR: Partial response; PD: Progression disease; PFS: Progression free survival; OS: Overall survival.